After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...

Gilead pounced to buy cell therapy company Kite in August last year for just under $12 billion, shortly before the biotech firm gained approval for its CAR-T cancer therapy Yescarta. Now Gilead is ...

Cognizant (CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (GILD) that aims to unlock even greater value for Gilead as it advances ...

TEANECK, N.J., Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD ...

More Bonds of Gilead Sciences Inc. Moody’s Daily Credit Risk Score About the Gilead Sciences Inc.-Bond (US375558CB72) The Gilead Sciences Inc.-Bond has a maturity date of 11/15/2029 and offers a ...

$ 96.72-0.48-0.49% ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...

After hours: 7:40:13 p.m. EST ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Please view our affiliate disclosure. Creating a strong brand identity is one of the most important aspects of a business. A well-designed logo is often the first impression a company makes on ...